SPAC for 2025 BLA: Non-viral gene therapy biotech enGene, steered by ex-Mythic leaders, finds Forbion blank check
Nearing a Phase II for its non-viral gene therapy, a small Canadian biotech plans to combine with a Forbion-led blank check company to land a seat on Nasdaq and get to an FDA approval request in the first half of 2025.
With the help of additional backers like Omega Funds, Cowen Healthcare Investments, BVF Partners and others, enGene will snag about $135 million in capital from its proposed marriage with Forbion European Acquisition Corp. The SPAC, formed by the Dutch VC fund just as blank checks were going out of vogue, went through a $110 million IPO in December 2021. It had about $111 million in its trust at the end of March.
To read Endpoints News become a free subscriber
Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters